万泰生物：公司九价HPV疫苗产品首次获得批签发证明

Core Viewpoint - Wante Bio's nine-valent HPV vaccine has received the production approval certificate, marking its official market launch, which is expected to enhance the company's revenue and profit growth potential [1] Group 1: Product Launch - Wante Bio's subsidiary, Xiamen Wante Canghai Biotechnology Co., has produced the nine-valent HPV vaccine, which has now been certified by the China Food and Drug Administration [1] - The approval signifies the first time the nine-valent HPV vaccine has received a production certificate, allowing it to be sold in the market [1] Group 2: Market Positioning - The introduction of the nine-valent HPV vaccine will enrich and optimize Wante Bio's product lineup, creating new revenue and profit growth points [1] - The combination of the nine-valent HPV vaccine with the existing two-valent HPV vaccine will form a differentiated and competitive product matrix, catering to diverse market segments and consumer needs [1] Group 3: Pricing Strategy - The price of Wante Bio's nine-valent HPV vaccine, "Xinkening 9," is set at 499 yuan per dose, which is only 40% of the price of imported nine-valent HPV vaccines [1]